BIOD-G Biodel Inc.
(A Development Stage Company)Balance Sheets
(In thousands, except share and per share amounts)September 30,20092010ASSETSCurrent:Cash and cash equivalents
22,922Restricted cash—150Marketable securities, available for sale—6,001Taxes receivable752116Other receivable—11Prepaid and other assets482365Total current assets55,87429,565Property and equipment, net3,6952,998Intellectual property, net5653Total assets
1,989Accrued expenses:Clinical trial expenses5,6471,362Payroll and related1,117357Accounting and legal fees325300Severance183—Other643334Income taxes payable16545Total current liabilities9,0874,387Common stock warrant liability—4,169Total long term liabilities—4,169CommitmentsStockholders' equity:Preferred stock, $.01 par value; 50,000,000 shares authorized, none outstanding——Common stock, $.01 par value; 100,000,000 shares authorized; 23,803,672 and 26,399,764 issued and outstanding238264Additional paid-in capital176,764188,549Accumulated other comprehensive loss—1Deficit accumulated during the development stage(126,464)(164,754)Total stockholders' equity50,53824,060Total liabilities and stockholders' equity
(A Development Stage Company)Statements of Operations
(In thousands, except share and per share amounts)December 3,2003(Inception) toYear Ended September 30,September 30,2008200920102010Revenue$
8212;Operating expenses:Research and development32,55432,32526,177116,228General and administrative14,80010,99410,98047,625Total op
|SOURCE Biodel Inc.|
Copyright©2010 PR Newswire.
All rights reserved